Crocetin inhibits beta-amyloid fibrillization and stabilizes beta-amyloid oligomers

Biochemical and Biophysical Research Communications

Volumn 414, Issue 1, 2011, Pages 79-83

  Ahn, Joon Ho ^a   Hu, Yang ^a   Hernandez, Michael ^a   Kim, Jin Ryoun ^a  

^a JACOBS ENGINEERING   (United States)

Author keywords

Beta amyloid; Crocetin; Fibril; Oligomer; Protein aggregation

Indexed keywords

AMYLOID BETA PROTEIN; CROCETIN; OLIGOMER;

ARTICLE; DRUG EFFECT; FIBER; PRIORITY JOURNAL; PROTEIN AGGREGATION;

AMINO ACID SEQUENCE; AMYLOID; AMYLOID BETA-PEPTIDES; CAROTENOIDS; FLUORESCENCE; HUMANS; MOLECULAR SEQUENCE DATA; THIAZOLES;

EID: 80054071097     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.09.025     Document Type: Article

References (39)

1. Aguzzi A., O'Connor T. Protein aggregation diseases: pathogenicity and therapeutic perspectives. Nat. Rev. Drug Discov. 2010, 9:237-248.
2. Citron M. Alzheimer's disease: strategies for disease modification. Nat. Rev. Drug Discov. 2010, 9:387-398.
3. Kayed R., Head E., Thompson J.L., McIntire T.M., Milton S.C., Cotman C.W., Glabe C.G. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 2003, 300:486-489.
4. Barghorn S., Nimmrich V., Striebinger A., Krantz C., Keller P., Janson B., Bahr M., Schmidt M., Bitner R.S., Harlan J., Barlow E., Ebert U., Hillen H. Globular amyloid beta-peptide oligomer - a homogenous and stable neuropathological protein in Alzheimer's disease. J. Neurochem. 2005, 95:834-847.
5. Lambert M.P., Barlow A.K., Chromy B.A., Edwards C., Freed R., Liosatos M., Morgan T.E., Rozovsky I., Trommer B., Viola K.L., Wals P., Zhang C., Finch C.E., Krafft G.A., Klein W.L. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc. Natl. Acad. Sci. USA 1998, 95:6448-6453.
6. Singer M., Stidwill R.P., Nathan A., Gainer J.L. Intravenous crocetinate prolongs survival in a rat model of lethal hypoxemia. Crit. Care Med. 2000, 28:1968-1972.
7. Kanakis C.D., Tarantilis P.A., Tajmir-Riahi H.A., Polissiou M.G. Crocetin, dimethylcrocetin, and safranal bind human serum albumin: stability and antioxidative properties. J. Agric. Food Chem. 2007, 55:970-977.
8. Gainer J.L., Jones J.R. The use of crocetin in experimental atherosclerosis. Experientia 1975, 31:548-549.
9. Nam K.N., Park Y.M., Jung H.J., Lee J.Y., Min B.D., Park S.U., Jung W.S., Cho K.H., Park J.H., Kang I., Hong J.W., Lee E.H. Anti-inflammatory effects of crocin and crocetin in rat brain microglial cells. Eur. J. Pharmacol. 2010, 648:110-116.
10. Asai A., Nakano T., Takahashi M., Nagao A. Orally administered crocetin and crocins are absorbed into blood plasma as crocetin and its glucuronide conjugates in mice. J. Agric. Food Chem. 2005, 53:7302-7306.
11. Carter D.C., Ho J.X. Structure of serum albumin. Adv. Protein Chem. 1994, 45:153-203.
12. Deane R., Wu Z., Zlokovic B.V. RAGE (yin) versus LRP (yang) balance regulates alzheimer amyloid beta-peptide clearance through transport across the blood-brain barrier. Stroke 2004, 35:2628-2631.
13. Milojevic J., Melacini G. Stoichiometry and affinity of the human serum albumin-Alzheimer's Abeta peptide interactions. Biophys. J. 2011, 100:183-192.
14. Hu Y., Su B., Kim C.S., Hernandez M., Rostagno A., Ghiso J., Kim J.R. A strategy for designing a peptide probe for detection of beta-amyloid oligomers. Chembiochem 2010, 11:2409-2418.
15. Teplow D.B. Preparation of amyloid beta-protein for structural and functional studies. Methods Enzymol. 2006, 413:20-33.
16. LeVine H. Quantification of beta-sheet amyloid fibril structures with thioflavin T. Methods Enzymol. 1999, 309:274-284.
17. Mertens M.L., Kagi J.H. A graphical correction procedure for inner filter effect in fluorescence quenching titrations. Anal. Biochem. 1979, 96:448-455.
18. Kubista M., Sjoback R., Eriksson S., Albinsson B. Experimental correction for the inner-filter effect in fluorescence spectra. Analyst 1994, 119:417-419.
19. Leese R.A., Wehry E.L. Corrections for inner-filter effects in fluorescence quenching measurements via right-angle and front-surface illumination. Anal. Chem. 1978, 50:1193-1197.
20. Palmier M.O., Van Doren S.R. Rapid determination of enzyme kinetics from fluorescence: overcoming the inner filter effect. Anal. Biochem. 2007, 371:43-51.
21. Kumar A., Bullard R.L., Patel P., Paslay L.C., Singh D., Bienkiewicz E.A., Morgan S.E., Rangachari V. Non-esterified fatty acids generate distinct low-molecular weight amyloid-beta (Abeta42) oligomers along pathway different from fibril formation. PLoS One 2011, 6:e18759.
22. Tew D.J., Bottomley S.P., Smith D.P., Ciccotosto G.D., Babon J., Hinds M.G., Masters C.L., Cappai R., Barnham K.J. Stabilization of neurotoxic soluble beta-sheet-rich conformations of the Alzheimer's disease amyloid-beta peptide. Biophys. J. 2008, 94:2752-2766.
23. Gellermann G.P., Byrnes H., Striebinger A., Ullrich K., Mueller R., Hillen H., Barghorn S. Abeta-globulomers are formed independently of the fibril pathway. Neurobiol. Dis. 2008, 30:212-220.
24. Necula M., Kayed R., Milton S., Glabe C.G. Small molecule inhibitors of aggregation indicate that amyloid beta oligomerization and fibrillization pathways are independent and distinct. J. Biol. Chem. 2007, 282:10311-10324.
25. Chiti F., Dobson C.M. Protein misfolding, functional amyloid, and human disease. Annu. Rev. Biochem. 2006, 75:333-366.
26. Trovato A., Chiti F., Maritan A., Seno F. Insight into the structure of amyloid fibrils from the analysis of globular proteins. PLoS Comput. Biol. 2006, 2:e170.
27. Petkova A.T., Ishii Y., Balbach J.J., Antzutkin O.N., Leapman R.D., Delaglio F., Tycko R. A structural model for Alzheimer's beta -amyloid fibrils based on experimental constraints from solid state NMR. Proc. Natl. Acad. Sci. USA 2002, 99:16742-16747.
28. Fernandez-Escamilla A.M., Rousseau F., Schymkowitz J., Serrano L. Prediction of sequence-dependent and mutational effects on the aggregation of peptides and proteins. Nat. Biotechnol. 2004, 22:1302-1306.
29. Alvarez A., Opazo C., Alarcon R., Garrido J., Inestrosa N.C. Acetylcholinesterase promotes the aggregation of amyloid-beta-peptide fragments by forming a complex with the growing fibrils. J. Mol. Biol. 1997, 272:348-361.
30. Yu L., Edalji R., Harlan J.E., Holzman T.F., Lopez A.P., Labkovsky B., Hillen H., Barghorn S., Ebert U., Richardson P.L., Miesbauer L., Solomon L., Bartley D., Walter K., Johnson R.W., Hajduk P.J., Olejniczak E.T. Structural characterization of a soluble amyloid beta-peptide oligomer. Biochemistry 2009, 48:1870-1877.
31. Miller Y., Ma B., Nussinov R. Polymorphism in Alzheimer Abeta amyloid organization reflects conformational selection in a rugged energy landscape. Chem. Rev. 2010, 110:4820-4838.
32. Lazo N.D., Grant M.A., Condron M.C., Rigby A.C., Teplow D.B. On the nucleation of amyloid beta-protein monomer folding. Protein Sci. 2005, 14:1581-1596.
33. Cerda-Costa N., Esteras-Chopo A., Aviles F.X., Serrano L., Villegas V. Early kinetics of amyloid fibril formation reveals conformational reorganisation of initial aggregates. J. Mol. Biol. 2007, 366:1351-1363.
34. Sandberg A., Luheshi L.M., Sollvander S., Pereira de Barros T., Macao B., Knowles T.P., Biverstal H., Lendel C., Ekholm-Petterson F., Dubnovitsky A., Lannfelt L., Dobson C.M., Hard T. Stabilization of neurotoxic Alzheimer amyloid-beta oligomers by protein engineering. Proc. Natl. Acad. Sci. USA 2010, 107:15595-15600.
35. Bernstein S.L., Dupuis N.F., Lazo N.D., Wyttenbach T., Condron M.M., Bitan G., Teplow D.B., Shea J.E., Ruotolo B.T., Robinson C.V., Bowers M.T. Amyloid-beta protein oligomerization and the importance of tetramers and dodecamers in the aetiology of Alzheimer's disease. Nat. Chem. 2009, 1:326-331.
36. Berger F., Hensel A., Nieber K. Saffron extract and trans-crocetin inhibit glutamatergic synaptic transmission in rat cortical brain slices. Neuroscience 2011, 180:238-247.
37. Glabe C.G. Structural classification of toxic amyloid oligomers. J. Biol. Chem. 2008, 283:29639-29643.
38. Yoshihara T., Takiguchi S., Kyuno A., Tanaka K., Kuba S., Hashiguchi S., Ito Y., Hashimoto T., Iwatsubo T., Tsuyama S., Nakashima T., Sugimura K. Immunoreactivity of phage library-derived human single-chain antibodies to amyloid beta conformers in vitro. J. Biochem. 2008, 143:475-486.
39. Hard T. Protein engineering to stabilize soluble amyloid beta-protein aggregates for structural and functional studies. FEBS J. 2011, 10.1111/j.1742-4658.2011.08295.x.